Dr. Aaron D. Schimmer
Receive the latest news, event invites, funding opportunities and more from the Ontario Institute for Cancer Research.
Dr. Schimmer’s clinical practice is focused on treating patients with acute leukemia and related disorders. His laboratory research focuses on developing new therapeutic strategies for leukemia by targeting dysregulated mitochondrial pathways in leukemia stem cells. Dr. Schimmer is the author of more than 320 publications with over 27,000 citations and is an inventor on more than 20 patent applications.
The Schimmer Lab is interested in developing new therapeutic strategies for AML (acute myeloid leukemia) that effectively target leukemic stem cells. Using genetic and chemical approaches, including high throughput screens, we identify biological vulnerabilities in the AML cells and stem cells with a focus on mitochondrial and metabolic pathways. Through these efforts, we discover new biological pathways important for the growth and viability of AML and highlight new therapeutic approaches for this disease.
Visit Dr. Schimmer’s PubMed page
Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z, Hurren R, Jitkova Y, Gronda M, Maclean N, Lai CK, Eberhard Y, Bartoszko J, Spagnuolo P, Rutledge AC, Datti A, Ketela T, Moffat J, Robinson BH, Cameron JH, Wrana J, Eaves CJ, Minden MD, Wang JC, Dick JE, Humphries K, Nislow C, Giaever G, Schimmer AD. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011;20:674-88. PMID: 22094260
Cole A, Wang Z, Coyaud E, Voisin V, Gronda M, Jitkova Y, Mattson R, Hurren R, Babovic S, Maclean N, Restall I, Wang X, Jeyaraju DV, Sukhai MA, Prabha S, Bashir S, Ramakrishnan A, Leung E, Qia YH, Zhang N, Combes KR, Ketela T, Lin F, Houry WA, Aman A, Al-Awar R, Zheng W, Wienholds E, Xu CJ, Dick J, Wang JC, Moffat J, Minden MD, Eaves CJ, Bader GD, Hao Z, Kornblau SM, Raught B, Schimmer AD. Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. Cancer Cell. 2015;27:864-76. PMID: 26058080
Ishizawa J *,Zarabi SF *, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R,Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Man Chun Ma J, Leber AB, Minden M, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD&, Andreeff M& Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality. Cancer Cell 2019;35:721-37 * and & Equal contribution (Schimmer and Andreeff are co-corresponding and senior authors). PMID: 31056398
Lee J, Khan DH, Hurren R, Xu M, Na Y, Kang H, Mirali S, Wang X, Gronda MV, Jitkova Y, MacLean N, Arruda A, Alaniz Z, Konopleva MY, Andreeff M, Minden MD, Zhang L, Schimmer AD. Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production. Blood. 2021:;138(3):234-245. PMID: 34292323
Thomas GE, Egan G, García-Prat L, Botham A, Voisin V, Patel PS, Hoff FW, Chin J, Nachmias B, Kaufmann KB, Khan DH, Hurren R, Wang X, Gronda M, MacLean N, O’Brien C, Singh RP, Jones CL, Harding SM, Raught B, Arruda A, Minden MD, Bader GD, Hakem R, Kornblau S, Dick JE, Schimmer AD. The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness. Nat Cell Biol. 2022 Jun;24(6):872-884. PMID: 35618834
Dr. Schimmer welcomes opportunities for collaboration in leukemia research, especially into mitochondria and metabolism as they relate to the disease.
